Price
Target price
€93.66
€93.66
-1.920%
-1.84
-1.920%
€125.35
06.08.26 / Tradegate
WKN: 529882 / Symbol: CORT / Name: Corcept / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corcept Therapeutics Inc. Stock
We can see a decrease in the price for Corcept Therapeutics Inc.. Compared to yesterday it has lost -€1.840 (-1.920%).
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 125 € there is a positive potential of 33.46% for Corcept Therapeutics Inc. compared to the current price of 93.66 €.
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Revenue growth" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Revenue growth" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | -1.920% | -8.713% | 16.987% | 54.861% | 36.970% | 229.789% | 414.615% |
| Pacira Pharmaceuticals | -1.850% | -9.402% | -4.505% | 12.766% | -1.852% | -39.429% | -58.431% |
| Supernus Pharmaceuticals | -1.060% | -7.882% | -10.526% | 15.432% | -13.023% | 30.769% | 66.964% |
| Collegium Pharmaceutical Inc | 0.000% | -1.282% | -5.521% | 21.260% | -25.604% | 55.556% | 79.070% |
Comments
Corcept Therapeutics (CORT) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock, up from $88.00.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target raised by HC Wainwright from $95.00 to $165.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) was upgraded by Truist Financial Corporation to "strong-buy".
Show more
Ratings data for CORT provided by MarketBeat
News
Corcept Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Corcept Therapeutics Incorporated? Here are five stocks we like better.
- Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing’s syndrome
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
Chief Financial Officer Mokari Atabak reported the sale of 40,000 shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) on July 15, 2026, according to an SEC Form 4 filing.
Transaction value
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
James N. Wilson, a director at Corcept Therapeutics Incorporated (NASDAQ:CORT), sold 10,000 shares of the company on July 15, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC